Brokerages Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) PT a

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among […]

Related Keywords

Blackrock , Massachusetts , United States , Frank Yocca , Richardi Steinhart , Driehaus Capital Management , Jefferies Financial Group , Vanguard Group Inc , Securities Exchange Commission , Bioxcel Therapeutics Company Profile , Blackrock Inc , Massachusetts Financial Services Co , Goldman Sachs Group , Bioxcel Therapeutics Inc , Nasdaq , Bioxcel Therapeutics , Get Rating , Marketbeat Ratings , Financial Group , Xcel Therapeutics Trading Down , Xcel Therapeutics , Exchange Commission , Street Corp , Capital Management , Massachusetts Financial Services , Financial Services , Bioxcel Therapeutics Daily , Nasdaq Btai , Obtai , Medical , Ratings , Consensus ,